NCT01177852撤回3 期
Multicenter Clinical Trial, Phase III, Controlled, Open, Parallel Group, Randomized, Comparing the Fixed Dose Combination of Diphenhydramine + Dropropizine + Pseudoephedrine and the Combined Use of Dropropizine and Fixed Dose Combination of Pseudoephedrine Hydrochloride + Brompheniramine Maleate Used Orally for Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2 to 12 Years Old, Suffering From Non-productive Cough and Acute Rhinitis.
Ache Laboratorios Farmaceuticos S.A.0 个研究点开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- Improvement of nasal congestion and cough
研究概览
简要总结
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no more than 5 consecutive days (without systemic/topic use of medication during this period) followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients between 2 and 12 years old, of both sexes;
- •Clinical condition compatible with acute rhinitis accompanied by nasal obstruction;
- •Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive days in duration;
- •Score greater than or equal to 3 points on the cough severity score (As per item 4.1.2);
- •Score greater than or equal to 2 points on the nasal obstruction severity score (As per item 4.1.3);
- •ICF signed by a parent/caregiver/representant;
- •Parent/Caregiver/Representant capacity, according to investigator evaluation, for compliance at the treatment and protocol requirements, fulfilling the regular visits;
排除标准
- •Non-productive cough with purulent smear, fever (axillar temperature superior than 37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection of upper and lower airways at 7 days before the screening/randomization visit;
- •Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or other determinants conditions of nasal congestion;
- •Previous diagnosis of asthma;
- •Patients under treatment for chronic allergy;
- •Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
- •Current use of systemic antibiotics for any reason;
- •Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3 of this protocol;
- •Participation in last one year of clinical protocols;
- •Any psychiatric diseases, including major depression;
- •Presence of mental retardation from any cause;
- •Diagnosis of renal or hepatic failure;
- •History of hypersensitivity to any component of the study drugs;
- •Relatives of sponsor´s or study site´s employee;
- •Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;
- •Patient or parent/caregiver/representant with a history of lack of compliance to treatment or previous treatment protocols;
- •Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
研究组 & 干预措施
Notuss® syrup
Experimental
Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
干预措施: diphenhydramine + dropropizine + pseudoephedrine (Drug)
Dropropizine + Pseudoephedrine and brompheniramine
Active Comparator
Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
干预措施: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir). (Drug)
结局指标
主要结局
Improvement of nasal congestion and cough
时间窗: Evaluated on the day 2 after beginning treatment
Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.
次要结局
- Improvement of nasal congestion and cough(Evaluated on the 7(±1) day after beginning treatment)
- Improvement of non-obstructive nasal symptoms(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Reduction of vomiting frequency episodes triggered by coughing(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Improvement of acute rhinitis signs(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Use of rescue medication(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Overall impression of improvement by the investigator(Evaluated on the day 2 and 7 (±1) after beginning treatment)
- Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.(Will be evaluated during the 7(± 1) days of treatment)
研究者
相似试验
已完成
3 期
Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of RhinitisNasal Congestion and InflammationsRhinitisNCT01393548Ache Laboratorios Farmaceuticos S.A.879
已完成
3 期
Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of RhinitisNasal Congestion and InflammationsRhinitisNCT01393561Ache Laboratorios Farmaceuticos S.A.167
撤回
3 期
Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute RhinitisNasal CongestionCoughNCT01199497Ache Laboratorios Farmaceuticos S.A.
进行中（未招募）
3 期
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Triple-Negative Breast CancerNCT06382142Sichuan Baili Pharmaceutical Co., Ltd.418
Unknown
3 期
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary HypercholesterolemiaPrimary HypercholesterolemiaHypertensionNCT04659070Hanlim Pharm. Co., Ltd.156